Exploring the Prognostic and Predictive Impact of Genomic Loss of Heterozygosity and Homologous Recombination Deficiency Alterations in Patients With Metastatic Colorectal Cancer

In pMMR/MSS mCRC, gLOH-high was associated with worse prognosis and higher benefit from the addition of anti-PD-L1 agents to chemotherapy. If confirmed in larger series, these results may inform the design of clinical trials.

Authors

Institutions

Publication Details

Journal
JCO Precision Oncology
Published
2025-04-01
DOI
https://doi.org/10.1200/po-24-00567
Primary Topic
PARP inhibition in cancer therapy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Exploring the Prognostic and Predictive Impact of Genomic Loss of Heterozygosity and Homologous Recombination Deficiency Alterations in Patients With Metastatic Colorectal Cancer

Eleonora Gusmaroli, Veronica Conca, Marco Maria Germani, Stefano Tamberi et al.
JCO Precision Oncology
PARP inhibition in cancer therapy
article

Exploring the Prognostic and Predictive Impact of Genomic Loss of Heterozygosity and Homologous Recombination Deficiency Alterations in Patients With Metastatic Colorectal Cancer

Eleonora Gusmaroli, Veronica Conca, Marco Maria Germani, Stefano Tamberi, Clara Ugolini, Mirella Giordano, Lisa Salvatore, Roberto Moretto, Mario Scartozzi, Sara Lonardi, Rossella Bruno, Gianluca Masi, Alessandro Minelli, Martina Carullo, Daniele Rossini, Filippo Pietrantonio, Carlotta Antoniotti, Maria Caterina De Grandis, Chiara Cremolini, Alessandro Passardi
article en

Abstract

In pMMR/MSS mCRC, gLOH-high was associated with worse prognosis and higher benefit from the addition of anti-PD-L1 agents to chemotherapy. If confirmed in larger series, these results may inform the design of clinical trials.

JCO Precision OncologyVol. 9(9)
Università Cattolica del Sacro Cuore (IT), University of Pisa (IT), University of Padua (IT), University of Cagliari (IT), Agostino Gemelli University Polyclinic (IT), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT), Azienda Unità Sanitaria Locale Della Romagna (IT), Istituto Oncologico Veneto (IT), Ospedale San Paolo (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Azienda Ospedaliera Universitaria Pisana (IT), University of Florence (IT)
Good health and well-being
Openalex Percentile: Top 89%
PARP inhibition in cancer therapy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.